Please login to the form below

Not currently logged in
Email:
Password:

Unlicensed sex drugs seized by MHRA

Enforcement officers from the UK's Medicines and Healthcare products Regulatory Agency seize nearly USD 709,263 worth of unlicensed medicines

Enforcement officers from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) have seized nearly GBP 350,000 (USD 709,263) worth of unlicensed medicines.

The drugs were discovered on 1 August 2007 at a secure lock-up facility in Uxbridge, West London and included Kamagra tablets and sachets, Lovegra and Apcalis, which are manufactured in India, but are unlicensed and untested despite claiming to treat male impotence. Investigations are ongoing.

Danny Lee-Frost, MHRA's head of criminal operations, said: ìThe type of medicines we seized cannot be guaranteed to be acceptably safe because they have not gone through the correct licensing regulatory process. At best these medicines could be a waste of money, at worst they could be severely detrimental to your health.î

If an individual is convicted of offences under the Medicines Act 1968, they can be sentenced to a maximum of two years imprisonment and/ or an unlimited fine. Where appropriate the MHRA will use the Proceeds of Crime Act 2002 to determine whether or not benefits were accrued through criminal activity and will recoup illicit earnings if the individual is found guilty.

7th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics